Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$10.47 +4.8%	$10.42	$7.80 ▼ $28.09	$544.82M	N/A	308,070 shs	471,042 shs
RLAY Relay Therapeutics	$3.35 +3.1%	$3.47	$1.77 ▼ $10.72	$560.34M	1.62	3.09 million shs	1.79 million shs
THTX Theratechnologies	$3.21 +0.3%	$2.87	$1.12 ▼ $3.22	$147.14M	0.52	262,167 shs	100,568 shs
TLRY Tilray Brands	$0.95 +3.3%	$0.55	$0.35 ▼ $1.98	$1.01B	1.85	47.84 million shs	290.15 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-2.06%	-10.16%	+2.88%	-23.39%	+998,999,900.00%
RLAY Relay Therapeutics	+0.93%	-10.96%	-9.72%	+14.84%	-51.49%
THTX Theratechnologies	+0.31%	+1.27%	+1.59%	+22.14%	+131.88%
TLRY Tilray Brands	+41.67%	+51.20%	+58.31%	+104.04%	-48.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	1.9975 of 5 stars	3.5	0.0	0.0	0.0	2.2	2.5	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	3.0857 of 5 stars	3.1	3.0	0.0	0.0	3.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	204.28% Upside
RLAY Relay Therapeutics	2.92	Moderate Buy	$17.25	414.93% Upside
THTX Theratechnologies	3.00	Buy	N/A	N/A
TLRY Tilray Brands	2.20	Hold	$1.92	101.65% Upside

Current Analyst Ratings Breakdown

Latest THTX, RLAY, BCAX, and TLRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
8/8/2025	RLAY Relay Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $19.00
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
RLAY Relay Therapeutics	$10.01M	57.70	N/A	N/A	$3.86 per share	0.87
THTX Theratechnologies	$85.87M	1.72	N/A	N/A	($0.55) per share	-5.84
TLRY Tilray Brands	$821.31M	1.27	$0.15 per share	6.37	$1.40 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$1.95	N/A	N/A	N/A	N/A	-41.49%	-37.43%	N/A
THTX Theratechnologies	-$8.31M	-$0.19	N/A	45.86	N/A	-10.85%	N/A	-9.83%	10/9/2025 (Estimated)
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest THTX, RLAY, BCAX, and TLRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	BCAX Bicara Therapeutics	-$0.54	-$0.50	+$0.04	-$0.50	N/A	N/A
8/7/2025	Q2 2025	RLAY Relay Therapeutics	-$0.49	-$0.41	+$0.08	-$0.41	$0.07 million	$0.70 million
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million
7/9/2025	Q2 2025	THTX Theratechnologies	-$0.01	-$0.09	-$0.08	-$0.09	$24.30 million	$17,729.00 billion
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
RLAY Relay Therapeutics	N/A	20.92	20.92
THTX Theratechnologies	N/A	0.84	0.65
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
RLAY Relay Therapeutics	96.98%
THTX Theratechnologies	N/A
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	N/A
RLAY Relay Therapeutics	4.32%
THTX Theratechnologies	N/A
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
RLAY Relay Therapeutics	330	172.41 million	164.96 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

THTX, RLAY, BCAX, and TLRY Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Stock Price Up 9.2% - Here's What Happened

August 12 at 3:01 PM | marketbeat.com

Promising Cannabis Stocks To Keep An Eye On - August 12th

August 12 at 2:29 PM | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Sees Unusually-High Trading Volume - Should You Buy?

August 12 at 1:09 PM | marketbeat.com

Is Tilray stock price rally a trap? history suggests selling

August 12 at 12:11 PM | invezz.comI

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands

August 12 at 7:07 AM | financialpost.comF

Tilray Brands: Is TLRY Stock The Next Big Thing?

August 12 at 7:01 AM | forbes.com

Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane's and Happy Flower Brands

August 12 at 7:00 AM | globenewswire.com

Traders Buy High Volume of Call Options on Tilray Brands (NASDAQ:TLRY)

August 12 at 2:13 AM | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Trading Up 14.4% - Time to Buy?

August 11 at 4:34 PM | marketbeat.com

Cannabis stocks surge as Trump consider reclassifying the drug

August 11 at 3:18 PM | proactiveinvestors.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Should You Buy?

August 11 at 1:54 PM | marketbeat.com

Tilray Brands Sees Unusually Large Options Volume (NASDAQ:TLRY)

August 11 at 11:32 AM | marketbeat.com

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

August 11 at 10:50 AM | cnbc.com

Why Tilray (TLRY) Stock Is Trading Up Today

August 8, 2025 | finance.yahoo.com

Tilray Brands (NASDAQ:TLRY) Trading Up 2.7% - Here's Why

August 8, 2025 | marketbeat.com

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

August 8, 2025 | zacks.com

Tilray Brands (NASDAQ:TLRY) Trading 2.1% Higher - Still a Buy?

August 7, 2025 | marketbeat.com

Best Canadian Cannabis Penny Stocks Under $5 to Watch Now

August 7, 2025 | marijuanastocks.comM

Tilray Brands Launches The Humble Seed Whole Wheat Protein Crackers at Whole Foods Market

August 7, 2025 | globenewswire.com

Traders Purchase High Volume of Put Options on Tilray Brands (NASDAQ:TLRY)

August 7, 2025 | americanbankingnews.com

Tilray Brands (NASDAQ:TLRY) Stock Price Down 1.9% - Here's What Happened

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

THTX, RLAY, BCAX, and TLRY Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$10.47 +0.48 (+4.80%)

Closing price 04:00 PM Eastern

Extended Trading

$10.48 +0.01 (+0.14%)

As of 06:08 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Relay Therapeutics NASDAQ:RLAY

$3.35 +0.10 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.34 0.00 (-0.15%)

As of 07:58 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Theratechnologies NASDAQ:THTX

$3.21 +0.01 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 +0.00 (+0.16%)

As of 04:12 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Tilray Brands NASDAQ:TLRY

$0.95 +0.03 (+3.32%)

Closing price 04:00 PM Eastern

Extended Trading

$0.93 -0.02 (-2.37%)

As of 08:00 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time